If you have just been told that you have HIV, the language around treatment can feel like a second diagnosis: ART, CD4, viral load, resistance. The short version is much simpler. HIV treatment uses antiretroviral therapy (ART) to bring the amount of virus in the blood down—usually to a level that routine tests cannot detect. That protects the immune system and allows most people receiving effective care to live long, healthy lives.
Treatment does not remove HIV from the body. It keeps the virus under control. Once someone takes ART and maintains an undetectable viral load, they do not transmit HIV through sex. You may know this as U=U: undetectable equals untransmittable.
The practical answer
ART is recommended for everyone with confirmed HIV and is normally started as soon as possible. The exact medicines must be chosen with an HIV clinician. Resistance, hepatitis B, pregnancy, kidney and liver health, other medicines and everyday practicalities can all affect that choice.
This is a general guide for adults, not a personal treatment plan. Do not start, stop or change HIV medicine on the strength of a web article.
What HIV treatment actually does
HIV infects cells involved in organising the immune response, particularly CD4 T cells. Left unchecked, it continues making copies of itself. Over time, that can weaken immunity and leave a person more vulnerable to infections, certain cancers and other illnesses.
Antiretroviral drugs interrupt different steps in the virus’s life cycle. That is why treatment uses a combination rather than relying on a single active medicine. It is harder for resistant virus to emerge when an effective combination keeps replication shut down.
This need not mean a handful of tablets. Several medicines can be combined in one daily pill, and there are now long-acting injections for some people whose HIV is already stable on treatment. Neither format is automatically better. The useful regimen is the one that is medically appropriate, tolerable and realistic to keep taking.
The laboratory target is viral suppression. “Undetectable” means that the test cannot measure HIV below its reporting threshold; it does not mean that the virus has disappeared. Treatment still needs to continue.
Why clinicians no longer wait to start ART
There was a time when doctors often waited for the CD4 count to fall before beginning treatment. A large randomised study helped settle the argument.
The START trial enrolled 4,685 adults whose CD4 counts were above 500 cells/mm³. Half were assigned to begin ART immediately; the others deferred treatment. Serious AIDS-related and non-AIDS events occurred less often in the immediate-treatment group. The difference became clear enough for the trial to be stopped early.
Current guidance now recommends ART for everyone with HIV, whatever the CD4 count. The US National Institutes of Health guidance says treatment should begin at diagnosis or as soon afterwards as practicable. For UK and European practice, the key frameworks are the British HIV Association treatment guideline and the European AIDS Clinical Society guidelines.
“Start promptly” is not the same as “skip the checks”. The clinic still confirms the diagnosis, takes baseline blood tests, checks current medicines and talks through access and readiness. Occasionally another illness changes the timing. More often, the work is about finding an option that can be started quickly and continued reliably.
How a regimen is chosen
A list of popular HIV drugs is not much help on its own. A combination that is an excellent first choice for one person may be wrong for someone else. Before making a recommendation, the clinician brings several details together.
| Question | Why the answer matters |
|---|---|
| Does the resistance test show any relevant mutations? | Existing resistance can make a drug ineffective before treatment even starts. |
| Is hepatitis B also present? | Some HIV drugs treat both viruses. Removing them carelessly can allow hepatitis B to flare. |
| How are the kidneys and liver working? | These results affect the options available and the monitoring needed. |
| Could the person be pregnant or planning pregnancy? | The regimen must support maternal health and prevent vertical transmission. |
| What else are they taking? | Antacids, anticonvulsants, tuberculosis drugs, supplements and herbal products can interact with ART. |
| Will the schedule work in real life? | Food requirements, pill size, privacy, travel and clinic attendance all matter. |
Heart, bone, metabolic and mental health may also influence the discussion. This is shared decision-making in a very practical sense: the clinical evidence narrows the options, then the person and clinician choose between them.
Guidelines move as the evidence moves. The World Health Organization’s December 2025 recommendations incorporated new drugs and regimens while keeping the focus on care that is effective, workable and accessible.
What happens after the first prescription?
The viral-load result shows whether treatment is suppressing HIV. It should fall after effective ART begins, although people do not all reach an undetectable result on the same timetable. CD4 tests help the team understand immune function, particularly near diagnosis or when the starting count is low.
Other blood tests depend on the medicines and the person’s health. They may include kidney and liver function, cholesterol or triglycerides, and blood sugar. These checks are not busywork: they help the team spot a problem before it becomes a reason to abandon an otherwise useful regimen.
One detectable viral-load result does not necessarily equal treatment failure. The timing of the test, missed doses, a recent illness or vaccination, laboratory variation and drug interactions may need to be considered. The pattern—and sometimes a repeat test—is more informative than one isolated number.
Side effects, interactions and missed doses
Modern ART is generally well tolerated, but “generally” is not “always”. Nausea, headache, altered sleep, diarrhoea or tiredness can occur when treatment begins. Some symptoms settle; others call for a change. It is better to tell the clinic than to struggle quietly or take an unplanned break.
Regular dosing keeps enough medicine in the body to suppress HIV. Repeated gaps can let the virus replicate and, with some regimens, select resistance. Still, adherence is not a test of character. Shift work, depression, unstable housing, privacy, travel and prescription problems are real barriers. Naming the problem gives the clinic, pharmacist or support service something they can help solve.
Over-the-counter does not mean interaction-free. St John’s wort, mineral supplements and some antacids can interfere with particular antiretrovirals. The HIV team should know about every prescribed medicine, supplement and herbal product.
U=U: what the evidence says
U=U is a statement about sexual transmission. A person who takes ART and maintains a viral load below 200 copies/mL does not transmit HIV to sexual partners. This conclusion is backed by a randomised trial and large prospective studies—not merely by reassurance or theory.
In PARTNER2, researchers followed serodifferent gay couples at 75 sites in 14 European countries. The couples reported 76,088 instances of condomless sex during eligible follow-up while the partner with HIV had a suppressed viral load. Fifteen partners acquired HIV, but genetic testing showed that none of those infections came from the partner in the study. There were zero linked transmissions.
Alongside earlier results in heterosexual and gay couples, that supports an effectively zero risk of sexual transmission while suppression is maintained. U=U does not prevent other sexually transmitted infections, and it depends on knowing that the viral load remains suppressed. If that is uncertain, the right next step is to ask the clinic rather than guess.
ART controls HIV; it does not cure it
HIV can remain in long-lived cells even when blood tests report an undetectable viral load. If effective ART is stopped, the virus will usually start replicating again. Someone who feels perfectly well still needs treatment and follow-up.
Be wary of claims that a diet, supplement or unlicensed product can clear HIV from the body. That is not supported by reliable clinical evidence and can become dangerous if it leads someone away from effective treatment.
When to contact the clinic
Contact the HIV clinic promptly if medicine is running out, doses are regularly being missed, side effects are making treatment difficult, a new medicine or supplement has been added, or pregnancy is possible. Persistent vomiting or diarrhoea also matters because it may affect absorption.
Seek urgent medical care now for difficulty breathing, collapse, marked confusion, severe chest pain, signs of a serious allergic reaction or another rapidly worsening illness. Do not wait for an online response. Do not stop ART abruptly unless a qualified clinician who understands the regimen has explained what to do.
Where the evidence is strong—and where it becomes personal
There is little serious disagreement about the foundations: ART protects health; starting early is better than waiting for immune damage; and sustained viral suppression prevents sexual transmission. Clinical guidelines, randomised trials and large cohorts point in the same direction.
The evidence cannot name the best regimen for an individual reader. Trials study groups of people. The person in front of a clinician may have resistance, hepatitis B, pregnancy, previous side effects or a competing medicine that was rare—or excluded—in a trial. Guidelines therefore provide preferred options and decision rules, not one prescription for everyone.
The 2025 EACS update is a useful reminder that this field does not stand still. New formulations arrive and evidence develops around long-acting treatment, prevention and health conditions that occur alongside HIV. We plan to review this guide after any major guideline change and at least every six months during its first year.
How we researched this guide
We compared current BHIVA, EACS, WHO and NIH recommendations with the peer-reviewed evidence behind early treatment and U=U. We gave most weight to clinical guidelines, randomised evidence and large prospective studies. The evidence search was completed on 4 September 2026.
FMJ’s free and delayed-access HIV journal listings provide a route into the research literature. Our Sources and Citation Policy explains how evidence is chosen and checked. Prof. Dr. Christian Hoffmann medically reviewed this article on 4 September 2026.
Frequently asked questions
How soon should HIV treatment start after diagnosis?
Current guidelines recommend ART for everyone with HIV and favour starting at diagnosis or as soon afterwards as practicable. Baseline results and individual circumstances still guide the exact regimen.
How long does treatment continue?
With current standard care, ART is lifelong. Medicines may be changed for side effects, interactions, resistance, pregnancy or convenience, but treatment should not be interrupted without specialist advice.
Can someone with an undetectable viral load pass HIV through sex?
No. When ART keeps the viral load below 200 copies/mL, the person does not transmit HIV through sex. That is the evidence behind U=U.
What should someone do after missing a dose?
The answer depends on the medicines and how much time has passed. Check the approved patient leaflet and contact the HIV clinic or pharmacist. Do not double the next dose unless the instructions or a clinician specifically say to do so.
In summary
HIV treatment works by blocking viral replication with a carefully chosen combination of antiretroviral medicines. Starting promptly protects the immune system and reduces serious illness. Maintaining an undetectable viral load also prevents sexual transmission. Those conclusions rest on strong evidence; choosing the right regimen remains a personal clinical decision.
This article provides general education and cannot diagnose HIV or select treatment for an individual. Do not change prescribed medicine without speaking to the clinician or pharmacist responsible for your care. Read the full FMJ Medical Disclaimer.